Tag: vasomotor menopausal symptoms vms treatment market size

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

In recent times, the market size for treating vasomotor menopausal symptoms (VMS) has seen significant growth. It is predicted to expand from $17.86 billion in 2024 to $19.19 billion in 2025, at a compound annual growth rate (CAGR) of 7.5%. Factors such as hormone replacement therapy (hrt), awareness about menopause, advancements in pharmaceuticals, and consumer demand have contributed to the growth in the historic period.

What Growth Rate Is Forecasted for the Vasomotor Menopausal Symptoms (VMS) Treatment Market by 2029?

The market size for the treatment of vasomotor menopausal symptoms (VMS) is predicted to experience robust growth in the upcoming years. The market is projected to surge to $24.81 billion by 2029, with a compounded annual growth rate (CAGR) of 6.6%. This prospective growth can be credited to factors such as tailored medication, non-hormonal advancements, nutritional and dietary strategies, telehealth, and digital health. Key future trends include the rise of natural and alternative methods, botanical and herbal solutions, support groups for menopause, and CBT (cognitive behavioral therapy).

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

Which Key Companies Are Shaping the Future of the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

Which Factors Are Driving Demand in the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?

The rise in the population experiencing menopause is anticipated to accelerate the expansion of the vasomotor menopausal symptom’s treatment market. Menopause, a natural biological occurrence, denotes the conclusion of a woman’s fertility years. This crucial stage of life generally happens in women aged 45 to 55, with 51 being the median age. The escalating number of women enduring menopause that necessitate remedies for symptoms like hot flashes and vaginal dryness globally is a crucial element propelling the growth of vasomotor menopausal symptoms (VMS) treatment market. In November 2022, for example, the Cuyuna Regional Medical Center, a US-based institute, predicted that about 1.1 billion women would enter menopause by 2025, due to increased female lifespan. In addition, it was estimated that the population undergoing menopause will rise by 1.6% annually until 2060. As a result, the surge in the menopause population is invigorating the growth of the vasomotor menopausal symptom’s treatment market. The initiatives taken by the government for improving the health of menopausal women are predicted to impel the growth of the vasomotor menopausal symptom’s treatment market onward. Government efforts for healthcare during menopause include financial support for groundbreaking research on menopausal transition, disease prevention, and studies related to pharmacological, clinical, and epidemiological aspects. These undertakings make up a significant part of wider initiatives for women’s health. For example, as per the Government of New South Wales, an Australia-based institution, in January 2023, the administration allocated $40.3 million over a period of four years (2022-2023 to 2025-2026) to establish up to 16 new programs dedicated to women experiencing severe menopausal symptoms. Therefore, these government activities to improve the health of menopausal women are fuelling the growth of the vasomotor menopausal symptoms’ treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp

How Is the Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmented by Several Divisions?

The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) Phenytoin: Hydantoins

8) Phenobarbital: Barbiturates

9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

What are the Emerging Market Trends Driving the Growth of the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?

Leading companies within the market for treatment of vasomotor menopausal symptoms are producing products like Veozah, and attaining necessary approvals to offer fresh treatment approaches and cater to the underserved medical necessities of patients. The sanctioning of new medicines for menopause aids in enhancing the effectiveness and security of existing treatments. For example, in May 2023, the US’s FDA approved the Japan-based Astellas Pharma Inc’s once-daily 45mg Veozah, a non-hormonal neurokinin 3 (NK3) receptor antagonist and the first of its kind authorized for treating VMS related to menopause, which can vary in severity from mild to severe. Veozah is a hormone-free treatment that obstructs a certain pathway in the brain that helps manage these symptoms, offering a new treatment approach for women experiencing these symptoms, especially those who cannot use or choose not to use hormone therapy. The granting of approval to Veozah underscores its potential as a novel medicine for managing menopausal symptoms.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

Which Regions Are Driving Growth in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051

This Report Delivers Insight On:

1. How big is the vasomotor menopausal symptoms (vms) treatment market, and how is it changing globally?

2. Who are the major companies in the vasomotor menopausal symptoms (vms) treatment market, and how are they performing?

3. What are the key opportunities and risks in the vasomotor menopausal symptoms (vms) treatment market right now?

4. Which products or customer segments are growing the most in the vasomotor menopausal symptoms (vms) treatment market?

5. What factors are helping or slowing down the growth of the vasomotor menopausal symptoms (vms) treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the vasomotor menopausal symptoms (vms) treatment industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2029?

The market for the treatment of vasomotor menopausal symptoms (VMS) has witnessed significant growth recently. The market size is projected to increase from $17.86 billion in 2024 to $19.19 billion in 2025, marking a compound annual growth rate (CAGR) of 7.5%. Factors such as hormone replacement therapy (HRT), awareness about menopause, advancements in pharmaceuticals, and consumer demand have contributed to this growth in the historical period.

Over the coming years, the treatment market for vasomotor menopausal symptoms (VMS) is predicted to experience significant growth. Its value is expected to reach $24.81 billion in 2029, with a compound annual growth rate (CAGR) of 6.6%. This projected growth during the forecast period can be credited to factors such as personalized medication, innovations in non-hormonal treatments, dietary and nutritional intervention strategies, and the integration of telemedicine and digital health. The forecast period will also see prime market trends like natural and alternative treatments, botanical and herbal solutions, menopause support forums, and cognitive behavioral therapy (cbt).

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

The surge in the population of menopausal women is set to drive the vasomotor menopausal symptom’s treatment market’s expansion. Menopause, a biological process that signifies the end of a woman’s fertility period, is a critical period in every woman’s life, happening between the ages of 45 and 55, with most women experiencing it around the age of 51. The growth in the number of women at this stage, needing management of symptoms like hot flashes and vaginal dryness, is a significant factor pushing the vasomotor menopausal symptoms (VMS) treatment market’s growth. As estimated by the US-based Cuyuna Regional Medical Center in November 2022, by 2025, 1.1 billion women globally are expected to be in menopause, owing to increased life expectancy. They also projected a 1.6% annual increase in the menopausal population until 2060. Hence, the rising population of menopausal women is spurring the growth of the vasomotor menopausal symptom’s treatment market. Furthermore, governmental health initiatives focused on menopausal women are anticipated to further the growth of the vasomotor menopausal symptom’s treatment market. These initiatives consist of funding for studies on menopausal transition, disease prevention, and research related to pharmacological, clinical, and epidemiological aspects. They form part of a comprehensive strategy focusing on numerous women’s health issues. To illustrate, the January 2023 report from the Government of New South Wales in Australia mentioned a government dedication of $40.3 million from 2022-2023 to 2025-2026 to initiate up to 16 new programs for women suffering from severe menopausal symptoms. Consequently, these governmental health initiatives for menopausal women are steering the growth of the vasomotor menopausal symptoms’ treatment market.

Which Segments in the Vasomotor Menopausal Symptoms (VMS) Treatment Offer the Most Growth?

The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) Phenytoin: Hydantoins

8) Phenobarbital: Barbiturates

9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=13051&type=smp

What Are the Fastest-Growing Geographies in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Current Market Growth and Trends in the Vasomotor Menopausal Symptoms (VMS) Treatment Industry?

Major firms in the vasomotor menopausal symptoms treatment market, such as Veozah, are advancing their products and securing approvals to deliver fresh treatment solutions and address patients’ unmet medical requirements. The licensing of novel menopause drugs offers enhanced effectiveness and safety compared to currently available treatments. For example, in May 2023, the FDA, a federal agency based in the US, granted approval to Japan’s Astellas Pharma Inc for their product, Veozah (fezolinetant) 45 mg to be taken once daily. This drug is used for treating mild to severe menopausal vasomotor symptoms (VMS), making it the first nonhormonal neurokinin 3 (NK3) receptor antagonist approved for this uses. It’s a hormone-free treatment that interferes with a brain pathway that manages these symptoms. It offers an additional treatment option for women experiencing these symptoms, especially those who cannot or choose not to undergo hormone therapy. The approval of Veozah underlines its promising future as a new drug for managing menopausal symptoms.

View the full report here:

https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

What Are the Key Elements That Define the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the vasomotor menopausal symptoms (vms) treatment market size evolved in recent years?

The vasomotor menopausal symptoms (VMS) treatment market has shown robust growth, set to expand from $17.86 billion in 2024 to $19.19 billion in 2025, with a 7.5% CAGR. Growth drivers include hormone replacement therapy (HRT), increased menopause awareness, pharmaceutical advancements, and rising consumer demand.

What are the predictions for the vasomotor menopausal symptoms (vms) treatment market size in the coming years?

The vasomotor menopausal symptoms (VMS) treatment market is forecasted to grow significantly, reaching $24.81 billion by 2029 at a CAGR of 6.6%. Growth drivers include advancements in personalized medicine, non-hormonal treatment innovations, dietary and nutritional interventions, and increased adoption of telemedicine and digital health solutions. Emerging trends include natural and alternative therapies, the rise of botanical and herbal remedies, menopause support groups, and the integration of cognitive behavioral therapy (CBT) into treatment strategies.

Get your vasomotor menopausal symptoms (vms) treatment market report here!

https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

What key factors are fueling the growth of the vasomotor menopausal symptoms (vms) treatment market?

The rise in the population of women going through menopause is expected to enhance the growth of the vasomotor menopausal symptom’s treatment market. Menopause is a natural occurrence that demarcates the conclusion of a woman’s fertility period. Typically, it transpires between the ages of 45 and 55, with the median age being roughly 51. The growing population of women experiencing menopause, and the ensuing need for treatment to manage symptoms like hot flashes and vaginal dryness, is a major factor propelling the vasomotor menopausal symptoms (VMS) treatment market’s growth. As an example, the Cuyuna Regional Medical Center in the US projected in November 2022 that 1.1 billion women would be menopausal by 2025, as life expectancy for women increases. Furthermore, the menopausal population is predicted to grow by 1.6% each year till 2060. Hence, the rise in the menopause population is fostering the growth of the vasomotor menopausal symptom’s treatment market. Government initiatives to improve women’s health during menopause are expected to catalyze the growth of the vasomotor menopausal symptoms’ treatment market. These initiatives include funding for innovative studies on menopausal transition, preventing illnesses, and researching various pharmacological, clinical, and epidemiological elements of menopause. These actions are integrated parts of comprehensive women’s health programs. In January 2023, the Government of New South Wales, an agency in Australia, initiated a $40.3 million investment spanning four years (from 2022-2023 to 2025-2026) to establish up to 16 new programs for women suffering from severe menopausal symptoms. Therefore, government initiatives geared towards improving women’s health during menopause are enhancing the growth of the vasomotor menopausal symptoms’ treatment market.

How is the global vasomotor menopausal symptoms (vms) treatment market divided into key segments?

The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) Phenytoin: Hydantoins

8) Phenobarbital: Barbiturates

9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

Who are the key firms paving the way for growth in the vasomotor menopausal symptoms (vms) treatment market?

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy’s Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.

Which trends are expected to transform the vasomotor menopausal symptoms (vms) treatment market?

Key players in the treatment market for vasomotor menopausal symptoms are working on creating new treatments like Veozah, and securing necessary approvals to enhance treatment options and address the underserved medical needs in patients. The sanctioning of new medicines for menopause presents better efficiency and safety in relation to current treatments. For example, Astellas Pharma Inc, a pharmaceutical firm based in Japan, was granted approval by the Food and Drug Administration (FDA), a US federal unit, in May 2023 for Veozah (fezolinetant) 45 mg once daily for treating menopausal vasomotor symptoms (VMS), which can be mild to severe. This is the initial nonhormonal neurokinin 3 (NK3) receptor antagonist to be sanctioned for addressing VMS related to menopause. It is a hormone-free solution that impedes a brain pathway that aids in managing these symptoms, providing an alternative treatment for women dealing with these symptoms, particularly those who cannot or do not wish to use hormone therapy. The authorization of Veozah underscores its promise as a new medication for managing menopausal symptoms.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13051

What regions are contributing significantly to the growth of the vasomotor menopausal symptoms (vms) treatment market?

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Browse Through More Similar Reports By The Business Research Company:

Insulin Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Polycystic Ovarian Syndrome Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Smart Insulin Pens Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR is Anticipated for the Vasomotor Menopausal Symptoms (VMS) Treatment Market During the Forecast Period, and Why?

The market size for the treatment of vasomotor menopausal symptoms (VMS) has witnessed robust growth in the recent past. The market, valued at $17.86 billion in 2024, is expected to reach $19.19 billion in 2025, expanding at a compound annual growth rate (CAGR) of 7.5%. Factors such as hormone replacement therapy (hrt), heightened awareness about menopause, advancements in pharmaceuticals, and consumer demand contribute to the growth observed in the historical period.

The market size for vasomotor menopausal symptoms (VMS) treatment is predicted to experience robust growth in the coming years. The market value is projected to reach $24.81 billion in 2029, growing at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period is influenced by factors such as individualized medicine, innovations in non-hormonal treatments, interventions involving nutrition and diet, digital health and telemedicine. Key trends throughout the forecasted period include natural and alternative treatment methodologies, botanical and herbal remedies, the emergence of menopause support groups, and the application of cognitive behavioral therapy (cbt).

What Key Drivers Are Accelerating the Growth of the Vasomotor Menopausal Symptoms (VMS) Treatment Market During the Forecast Period?

The rise in the population of women going through menopause is expected to enhance the growth of the vasomotor menopausal symptom’s treatment market. Menopause is a natural occurrence that demarcates the conclusion of a woman’s fertility period. Typically, it transpires between the ages of 45 and 55, with the median age being roughly 51. The growing population of women experiencing menopause, and the ensuing need for treatment to manage symptoms like hot flashes and vaginal dryness, is a major factor propelling the vasomotor menopausal symptoms (VMS) treatment market’s growth. As an example, the Cuyuna Regional Medical Center in the US projected in November 2022 that 1.1 billion women would be menopausal by 2025, as life expectancy for women increases. Furthermore, the menopausal population is predicted to grow by 1.6% each year till 2060. Hence, the rise in the menopause population is fostering the growth of the vasomotor menopausal symptom’s treatment market. Government initiatives to improve women’s health during menopause are expected to catalyze the growth of the vasomotor menopausal symptoms’ treatment market. These initiatives include funding for innovative studies on menopausal transition, preventing illnesses, and researching various pharmacological, clinical, and epidemiological elements of menopause. These actions are integrated parts of comprehensive women’s health programs. In January 2023, the Government of New South Wales, an agency in Australia, initiated a $40.3 million investment spanning four years (from 2022-2023 to 2025-2026) to establish up to 16 new programs for women suffering from severe menopausal symptoms. Therefore, government initiatives geared towards improving women’s health during menopause are enhancing the growth of the vasomotor menopausal symptoms’ treatment market.

Request Your Free Vasomotor Menopausal Symptoms (VMS) Treatment Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp

What Are the Leading Organizations Impacting the Vasomotor Menopausal Symptoms (VMS) Treatment Market’s Growth?

Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are:

• Pfizer Inc._x000D_

• Abbvie Inc._x000D_

• Novartis AG_x000D_

• Ausio Pharmaceuticals LLC_x000D_

• Teva Pharmaceutical Industries Ltd._x000D_

What Are the Latest Trends Leading to Disruption in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Key players in the treatment market for vasomotor menopausal symptoms are working on creating new treatments like Veozah, and securing necessary approvals to enhance treatment options and address the underserved medical needs in patients. The sanctioning of new medicines for menopause presents better efficiency and safety in relation to current treatments. For example, Astellas Pharma Inc, a pharmaceutical firm based in Japan, was granted approval by the Food and Drug Administration (FDA), a US federal unit, in May 2023 for Veozah (fezolinetant) 45 mg once daily for treating menopausal vasomotor symptoms (VMS), which can be mild to severe. This is the initial nonhormonal neurokinin 3 (NK3) receptor antagonist to be sanctioned for addressing VMS related to menopause. It is a hormone-free solution that impedes a brain pathway that aids in managing these symptoms, providing an alternative treatment for women dealing with these symptoms, particularly those who cannot or do not wish to use hormone therapy. The authorization of Veozah underscores its promise as a new medication for managing menopausal symptoms.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/vasomotor-menopausal-symptoms-vms-treatment-global-market-report

What Are the Core Categories and Segments in the Vasomotor Menopausal Symptoms (VMS) Treatment Market Driving Demand and Growth?

The vasomotor menopausal symptoms (VMS) treatment market covered in this report is segmented –

1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase Inhibitors), Atypical Antidepressants

2) By Fluoxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

3) By Paroxetine: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

4) Sertraline: Depression, Obsessive-Compulsive Disorder (OCD), Panic Disorder, Post-Traumatic Stress Disorder (PTSD), Social Anxiety Disorder, Premenstrual Dysphoric Disorder (PMDD)

5) Hormone Therapy: Estrogen Replacement Therapy (ERT), Progestin Therapy, Combined Hormonal Therapy (CHT), Testosterone Replacement Therapy (TRT)

6) Anticonvulsant: Hydantoins, Barbiturates, Benzodiazepines, Valproates, Succinimides, Carboxylic Acid Derivatives

7) Phenytoin: Hydantoins

8) Phenobarbital: Barbiturates

9) Other Drug Classes: Antibiotics, Analgesics, Antidiabetics, Antihypertensives, Anticoagulants, Immunosuppressants, Antipsychotics, Antihistamines

What Are the Key Regions Powering Growth in the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Are the Core Features That Define the Vasomotor Menopausal Symptoms (VMS) Treatment Market?

Vasomotor menopausal symptoms (VMS) treatment refers to the medical interventions and therapies used to alleviate or manage the various symptoms associated with menopause. Women experience the symptoms of VMS during menopause, which include hot flashes and night sweats. The treatment works by balancing hormone levels in the body and altering neurotransmitters in the brain.

Browse Through More Similar Reports By The Business Research Company:

Insulin Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/insulin-drugs-global-market-report

Polycystic Ovarian Syndrome Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/polycystic-ovarian-syndrome-treatment-global-market-report

Smart Insulin Pens Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/smart-insulin-pens-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: